Navigation Links
Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin
Date:1/12/2009

ctive DNA damage, irreversible G2 arrest and apoptosis. Voreloxin is currently being evaluated in a Phase 2 clinical trial (known as the REVEAL-1 trial) in previously untreated elderly AML patients and in a Phase 1b/2 clinical trial combining voreloxin with cytarabine for the treatment of patients with relapsed/refractory AML as well as in an ongoing Phase 2 single-agent trial in platinum-resistant ovarian cancer.

About Acute Myeloid Leukemia

AML is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.

About Ovarian Cancer

In the United States, ovarian cancer remains the leading cause of death from gynecologic malignancies and is the fifth leading cause of cancer death overall in women behind lung, breast, colorectal and pancreatic cancers. According to the American Cancer Society, in 2008 there will be an estimated 21,650 new cases and more than 15,000 deaths from ovarian cancer in the U.S. alone. Following frontline treatment, recurrence rates among ovarian cancer patients are high. Treatment options remain limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent.

About Sunesis Pharmaceuticals

Sunesis is a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics for the
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Sunesis to Present at Upcoming Conferences
2. Sunesis to Present at Upcoming Conferences
3. Sunesis Pharmaceuticals to Present at the Jefferies 2nd Annual Healthcare Conference
4. Sunesis Pharmaceuticals Expands Development Leadership Team to Focus on Late-Stage Development of Voreloxin (Formerly SNS-595)
5. Sunesis Pharmaceuticals to Report Financial Results for the First Quarter on May 8, 2008
6. Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
7. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
8. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
9. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
10. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
11. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/12/2014)... York (PRWEB) July 12, 2014 ... for various reagents used in the life ... driving the life science reagents market towards ... include manufacturers and providers of life science ... Market Report: http://www.transparencymarketresearch.com/life-sciences-reagents-analytical-reagents.html . , The ...
(Date:7/11/2014)... WEST PALM BEACH, Fla. , July 11, 2014 ... wide variety of high-quality peptides that are used solely ... online. To honor two successful years in business, Maxim ... Performance LLC, has just launched a new and updated ... addition, the research blog section has been updated with ...
(Date:7/11/2014)... , Not for release, publication or distribution (in ... where to do so would constitute a violation of the ... or the "Company") (LSE: SHP, NASDAQ: SHPG ) ... held a meeting with representatives of AbbVie. This ... or approval of AbbVie. A further update will ...
(Date:7/11/2014)... Research and Markets  has announced the ... Global Industry Analysis, Size, Share, Growth, Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 Transfection is ... or RNA) into cells. This technology helps the cells ... protein metabolism by affecting the nuclear genes. The transfection ...
Breaking Biology Technology:Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 2Transparency Market Research: Life Science Reagents Market- PCR Reagent Kits, Cell and Tissue Culture, Flow Cytometry, Electrophoresis and Chromatography 3Maxim Peptide Celebrates Second Anniversary Online with an Updated Website and Special Deals Section 2Shire plc - Statement re: Media Speculation 2International Transfection Technology Market - Industry Analysis, Size, Share, Growth, Trends and Forecast to 2019 2
... Scientific Group Inc. (OTC Bulletin Board: BMSN)( ... wholly owned subsidiary, announced today they have jointly submitted ... Research and Materiel Command (USAMRMC) for consideration of funding ... (ASCs) harvested from liposuction for treating Traumatic Brain Injury ...
... Calif., May 4 Pulse Systems announced today that ... facility through the Structured Finance Group at Fifth Third ... million term loan and a $1.5 million revolving working ... arrangement of this scope in today,s challenging banking environment ...
... May 4 Arno Therapeutics, Inc. (OTC Bulletin Board: ... today announced that it has voluntarily filed a Form ... order to deregister its common stock under the Securities ... effective immediately, Arno,s obligation to file periodic and other ...
Cached Biology Technology:Bio-Matrix Scientific Group & Entest BioMedical Submit Research Proposal to U.S. Army for Funding Adipose-Derived Stem Cells to Treat Traumatic Brain Injury 2Pulse Systems Announces New $8.5 Million Credit Facility 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 2Arno Therapeutics to Deregister its Common Stock under the Exchange Act 3
(Date:7/11/2014)... Society shows that no-take zones in Belize can ... lobster, conch, and fish recover from overfishing, but ... The reporttitled "Review of the Benefits of No-Take ... no-take areas around the world. The report was ... in marine protected areas and fisheries management. The ...
(Date:7/11/2014)... 2014--Researchers at the Department of Energy,s Oak Ridge ... presented by R&D Magazine in recognition of the ... recognize the tremendous value of our National Labs," ... development at the National Labs continues to help ... the scientific and technological innovations necessary to remain ...
(Date:7/11/2014)... burning in eastern New South Wales, Australia when NASA,s ... 03:35 UTC on July 11 (12:35 p.m. local time/11:35 ... eastern New South Wales (NSW), the Moderate Resolution Imaging ... the region and spotted smoke (light brown) from various ... are outlined in red. , The New South Wales, ...
Breaking Biology News(10 mins):Belize's lobster, conch, and fish populations rebuild in no-take zones 2ORNL wins eight R&D 100s 2ORNL wins eight R&D 100s 3ORNL wins eight R&D 100s 4
... to 15 percent of couples of childbearing age struggle with ... new hope with Cornell researchers' identification of a mutation in ... is the first time that a dominant mutation that leads ... researchers say they can now look for similar mutations in ...
... research in France on patients diagnosed with cryptococcosis ... patients infected by HIV and who are profoundly ... 5 2007 in PLoS Medicine, uncovers parameters associated ... sex and the infecting serotype. In light of ...
... a combination of radiation seed implants and external beam ... disease 15 years following their treatment, according to a ... Oncology*Biology*Physics, the official journal of ASTRO. , This study ... Institute. Doctors wanted to look at the combination of ...
Cached Biology News:Researchers find gene mutation that causes infertility in male mice 2New recommendations against a major opportunistic infection -- cryptococcosis 2New recommendations against a major opportunistic infection -- cryptococcosis 3
... derivatives that have mutations in both the ... genes, which greatly enhances disulfide bond formation ... expression in Origami(DE3) yielded 10-fold more active ... overall expression levels were similar (1). Origami ...
... Blunt TOPO PCR Cloning ... designed for cloning and ... PCR products. The pCR4Blunt-TOPO ... Cloning and greater than ...
... CELLection Dynabeads (4.5 m) coated with the ... EpCAM and DNase Releasing Buffer. For ... tumour cells directly from blood, bone marrow ... enriched from bone marrow. Enriched cells are ...
Recombinant Human CCL21/6Ckine (Mucin Stalk Chimera)...
Biology Products: